Viatris Inc (VTRS)

Viatris is a global healthcare company formed in November 2020 through the combination of Mylan and Pfizer's Upjohn business, with a mission to empower people worldwide to live healthier at every stage of life regardless of geography or circumstance. Headquartered in the U.S. with global centers in Pittsburgh, Pennsylvania, Shanghai, China, and Hyderabad, India, the company employs approximately 37,000 people and delivers high-quality medicines to patients in more than 165 countries and territories. Viatris' portfolio comprises more than 1,400 approved molecules spanning more than 10 major therapeutic areas—including cardiovascular health, oncology, infectious diseases such as HIV/AIDS, hepatitis and tuberculosis, and noncommunicable diseases—offering globally recognized iconic and key brands, generics, complex generics, and OTC products; the company has identified ophthalmology, gastrointestinal, and dermatology as three core global therapeutic areas going forward, bolstered by 2023 acquisitions of Oyster Point (ophthalmic disease therapeutics, including the commercial asset Tyrvaya) and Famy Life Sciences (ophthalmology pipeline).

The company operates approximately 40 manufacturing sites worldwide producing oral solid doses, injectables, complex dosage forms, and APIs, with significant manufacturing, warehousing and distribution activities in the U.S., Puerto Rico, Singapore, India, Australia, China, and certain E.U. countries including Ireland; as part of a strategic reshaping announced in 2022, Viatris is divesting its API business (other than select development capabilities), women's healthcare (contraceptives), and Upjohn Distributor Markets, and completed the contribution of its biosimilars portfolio to Biocon Biologics in November 2022 in exchange for cash and equity consideration. Viatris serves customers including retail and pharmacy establishments, wholesalers and distributors, payers, insurers, governments, and institutions such as hospitals, with its largest customers being McKesson Corporation, AmerisourceBergen Corporation, and Cardinal Health, Inc., each representing meaningful percentages of consolidated net sales; the company manages its business on a geographic basis through skilled sales and marketing teams, and leverages licensing and partnership agreements, including its "Global Healthcare Gateway" platform, to expand its pipeline with novel, complex, and first-to-market generic and branded products such as biosimilars and long-acting injectables, while pursuing sustainability goals related to access to medicine, diversity, equity and inclusion, and environmental impact.